Skip to main content
. Author manuscript; available in PMC: 2010 Apr 15.
Published in final edited form as: Cancer Res. 2009 Apr 7;69(8):3537–3544. doi: 10.1158/0008-5472.CAN-08-3386

Figure 2. GCC-specific CD8+ T cell responses.

Figure 2

A, GCC-specific CD8+ T cell responses in GCC+/+ C57BL/6 mice following LacZ-AV (control) or GCC-AV immunization, measured by IFNγ ELISpot employing GCC-expressing colorectal cancer cells as stimulators. B, βgalactosidase-specific CD8+ T cell responses in GCC+/+ C57BL/6 mice following LacZ-AV or GCC-AV (control) immunization, measured by IFNγ ELISpot employing β-galactosidase-expressing colorectal cancer cells as stimulators. Data in A and B indicate pooled analysis of N=2 mice per group, and are representative of six independent experiments (*** P <0.001, two-sided Student's t test). C, GCC-specific CD8+ T cell responses in GCC+/+ (+/+) and GCC-/- (-/-) C57BL/6 mice following GCC-AV immunization, measured by IFNγ ELISpot as in A. Data indicate pooled analysis of N=2 mice per group, and are representative of two independent experiments (** P <0.01, two-sided Student's t test). D, SIINFEKL-specific CD8+ T cell responses in GCC+/+ (+/+) and GCC-/- (-/-) C57BL/6 mice following NP/SIINFEKL-AV immunization, measured by IFNγ ELISpot upon restimulation with SIINFEKL-expressing stimulator cells. Data are representative of three independent experiments examining SIINFEKL or βgalactosidase -specific responses (# P >0.9, two-sided Student's t test). Error bars in A-D indicate standard deviation.